Gout and erectile dysfunction often occur in the same men, and recent research suggests that their overlap is more than coincidence. Gout is an inflammatory arthritis caused by monosodium urate crystals, while erectile dysfunction (ED) is the persistent inability to achieve or maintain an erection adequate for satisfactory sexual activity. They affect different organs, but both are closely tied to vascular health, metabolic disease, inflammation, and medication use.
Gout and Erectile Dysfunction: What Studies Show
The relationship is supported mainly by observational research. A 2026 systematic review and meta-analysis by Mao and colleagues included 11 studies with more than 446,000 participants. Men with gout had a 37% higher relative risk of ED than controls. The analysis also found lower average testosterone in men with gout or hyperuricemia, although hormone findings varied among studies.[1]
Earlier meta-analyses reached similar, more conservative estimates. Luo and colleagues pooled eight studies involving 355,761 participants and reported a 20% higher risk of ED among men with gout.[2] A separate review by Duan and colleagues found an adjusted odds ratio of 1.18 after accounting for age and comorbidities.[3] These estimates are meaningful at a population level, but none proves that uric acid itself directly causes erection problems.
A 2024 cross-sectional study provides a clue about what may connect the conditions. Yigit and colleagues evaluated 134 men with gout and 104 controls, measuring erectile function and carotid intima-media thickness, a marker of subclinical atherosclerosis. ED, hypertension, high cholesterol, insulin resistance, and increased carotid thickness were all more common in the gout group. In multivariable analysis, increased carotid thickness was the only independent factor associated with ED. Among men who had both gout and increased carotid thickness, 97.9% had ED.[4]
The finding does not mean that nearly every man with gout will develop ED. It came from a selected clinical sample, and cross-sectional research cannot determine which problem came first. It does support a broader interpretation: vascular disease burden may be more important than the uric acid number alone.
Why the Conditions May Overlap
An erection is a vascular event. Sexual stimulation triggers nitric oxide release, allowing smooth muscle in penile arteries and erectile tissue to relax. Blood inflow rises, while venous outflow is temporarily restricted. Endothelial dysfunction, a state in which blood vessels respond poorly to normal signals, can weaken this process before symptoms appear in larger arteries.
Gout is also increasingly understood as part of a systemic risk pattern. Hyperuricemia often travels with hypertension, obesity, insulin resistance, type 2 diabetes, chronic kidney disease, sleep apnea, and dyslipidemia. Each can independently impair endothelial function and raise ED risk. Alcohol intake, low physical activity during painful flares, and smoking may add further effects.
Inflammation is another plausible bridge. During a gout flare, urate crystals activate the NLRP3 inflammasome and stimulate inflammatory mediators including interleukin-1 beta. Even between flares, some patients have persistent low-grade inflammation. Oxidative stress can reduce nitric oxide bioavailability, while inflammatory signaling may make the vascular lining less responsive.
However, a plausible mechanism is not the same as proven causation. Serum uric acid can behave as an antioxidant in some biological settings and a pro-oxidant in others. Studies use different definitions of gout, hyperuricemia, and ED, and residual confounding is difficult to eliminate. The most defensible conclusion is that gout identifies a group in whom clinicians should look carefully for vascular and metabolic contributors to ED.
Uric Acid, Testosterone, and Medications
The 2026 meta-analysis found lower testosterone on average among men with gout or hyperuricemia, but this does not establish that uric acid suppresses testosterone directly. Obesity, insulin resistance, chronic illness, sleep disruption, and certain medications can influence both hormone levels and sexual function. Testosterone also varies by time of day and should not be diagnosed as low from a single untimed test.
Men with reduced libido, fatigue, loss of body hair, reduced morning erections, or infertility may warrant morning total testosterone testing. If the result is low, guidelines generally recommend confirmation on another morning along with evaluation of the cause. Testosterone treatment is not a routine gout therapy and does not reliably correct vascular ED when testosterone is normal.
Medication questions require similar care. A 2022 propensity-matched cohort study compared men with gout treated with febuxostat or allopurinol. Febuxostat use was associated with a higher recorded ED risk than allopurinol, particularly in men aged 19 to 64.[5] Because treatment selection in routine care is not random, kidney function, cardiovascular risk, gout severity, and other factors may have influenced the result. The study should not prompt anyone to stop or switch urate-lowering therapy without a prescriber.
Colchicine and short courses of anti-inflammatory treatment are used for flares, while allopurinol, febuxostat, and other strategies lower urate over time. None is an established ED treatment. Effective gout control may improve mobility, sleep, and overall well-being, but evidence that urate lowering alone restores erectile function remains insufficient.
What Men With Both Conditions Should Check
Persistent ED deserves a structured assessment rather than being attributed automatically to age or gout. A clinician will usually ask when symptoms began, whether they are consistent or situational, whether spontaneous or morning erections remain, and whether libido or ejaculation has changed. Medication, alcohol, tobacco, sleep, mood, relationship context, pelvic surgery, and neurologic symptoms all matter.
The physical assessment may include blood pressure, body composition, pulses, and a focused genital examination. Common laboratory tests include hemoglobin A1c or fasting glucose and a lipid panel. Kidney function is especially relevant because it affects urate handling and medication choices. Morning testosterone, thyroid testing, or other studies may be appropriate when symptoms point to a hormonal cause.
ED can precede clinically obvious cardiovascular disease because penile arteries are smaller than coronary or carotid arteries. New ED in a man with gout, hypertension, diabetes, smoking history, or reduced exercise tolerance should therefore trigger cardiovascular risk review. Chest pressure, unexplained shortness of breath, fainting, or symptoms during exertion require prompt medical evaluation before sexual activity or ED medication is discussed.
Men can also reduce shared risk factors. Regular aerobic and resistance exercise may support endothelial function, metabolic control, and erectile health. Weight reduction can lower urate and improve erections in men with excess adiposity. Limiting heavy alcohol intake, avoiding tobacco, managing sleep apnea, and following an individualized gout diet may help. Hydration is sensible during illness and exercise, but drinking extreme amounts of water is not a treatment for ED.
More evidence-based guidance on circulation, hormones, and sexual function is available in the men's health library.
Treatment of Erectile Dysfunction in Men With Gout
Treatment depends on the cause and the man's cardiovascular status. Phosphodiesterase type 5 inhibitors enhance the nitric oxide–cyclic GMP pathway and are first-line therapy for many men. They support the natural erectile response to sexual stimulation; they do not generate desire automatically.
These medicines must not be taken with nitrates because the combination can cause a dangerous fall in blood pressure. Prescribers also review alpha-blockers, kidney and liver function, cardiovascular stability, and other medications. Severe chest pain, sudden vision or hearing changes, or an erection lasting more than four hours requires urgent care.
Psychological and relationship factors may coexist with vascular disease. Painful flares, fear of another flare, poor sleep, depression, and reduced confidence can affect arousal and performance. Counseling or sex therapy may be useful alongside medical treatment, particularly when symptoms vary by situation.
Conclusion
Gout and ED share a clinically important association, but the evidence points toward overlapping vascular, inflammatory, and metabolic risk rather than a simple one-cause explanation. Recent research suggests that men with gout experience ED more often, especially when subclinical atherosclerosis and cardiometabolic disease are present. The practical response is to manage gout appropriately while evaluating blood pressure, glucose, lipids, kidney function, hormones when indicated, lifestyle factors, and cardiovascular symptoms.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans, including Red Pill, starting with a free online assessment at questionnaire.getonyxmd.com.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
Mao J, Xu M, Tang Y, Chen J, Zhou J, Wu D. Gout, Hyperuricemia, and Male Reproductive Health: A Systematic Review and Meta-Analysis. Frontiers in Immunology. 2026;17:1889720. doi:10.3389/fimmu.2026.1889720
Luo L, Xiang Q, Deng Y, et al. Gout is associated with elevated risk of erectile dysfunction: a systematic review and meta-analysis. Rheumatology International. 2019;39:1527-1535. doi:10.1007/s00296-019-04365-x
Duan X, Zhang J, Zhang L, et al. Association between Gout and Erectile Dysfunction: A Systematic Review and Meta-Analysis. PLOS ONE. 2016;11(12):e0168784. doi:10.1371/journal.pone.0168784
Yigit E, Yasar S, Can M, Bayraktar Z. Gout and erectile dysfunction: Increased carotid intima-media thickness is independently associated with greater likelihood for erectile dysfunction. Archives of Rheumatology. 2024;39(3):393-403. doi:10.46497/ArchRheumatol.2024.10486
Lee HY, Lee WJ, Tseng CH, et al. Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study. Drugs. 2022;82(18):1717-1726. doi:10.1007/s40265-022-01816-x
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.